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Abstract
Background: Over the last decade several phase III microbicides trials have been conducted in developing countries.
However, laboratories in resource constrained settings do not always have the experience, infrastructure, and the capacity
to deliver laboratory data meeting the high standards of clinical trials. This paper describes the design and outcomes of a
laboratory quality assurance program which was implemented during a phase III clinical trial evaluating the efficacy of the
candidate microbicide Cellulose Sulfate 6% (CS) [1].
Methodology: In order to assess the effectiveness of CS for HIV and STI prevention, a phase III clinical trial was conducted in
5 sites: 3 in Africa and 2 in India. The trial sponsor identified an International Central Reference Laboratory (ICRL),
responsible for the design and management of a quality assurance program, which would guarantee the reliability of
laboratory data. The ICRL provided advice on the tests, assessed local laboratories, organized trainings, conducted
supervision visits, performed re-tests, and prepared control panels. Local laboratories were provided with control panels for
HIV rapid tests and Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) amplification technique. Aliquots from respective
control panels were tested by local laboratories and were compared with results obtained at the ICRL.
Results: Overall, good results were observed. However, discordances between the ICRL and site laboratories were identified
for HIV and CT/NG results. One particular site experienced difficulties with HIV rapid testing shortly after study initiation. At
all sites, DNA contamination was identified as a cause of invalid CT/NG results. Both problems were timely detected and
solved. Through immediate feedback, guidance and repeated training of laboratory staff, additional inaccuracies were
prevented.
Conclusions: Quality control guidelines when applied in field laboratories ensured the reliability and validity of final study
data. It is essential that sponsors provide adequate resources for implementation of such comprehensive technical
assessment and monitoring systems.
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Introduction
Microbicides are female initiated methods for the prevention of
HIV and other sexually transmitted infections (STIs). Several
phase III clinical trials assessing the effectiveness of microbicides
have been conducted over the last decade. Trials were mostly
implemented in developing countries, where the need for
microbicides is the highest in view of the relatively high HIV
incidence rates among women.
Large scale multi-centre phase III clinical trials often face
challenges in terms of adequate and appropriate clinical study
facilities, equipment and staff. This may especially be true for the
local laboratories delivering services for trials, which have to
ensure delivery of accurate and reliable data. Laboratories
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with multi-site clinical trials conducted under an Investigational
New Drug application, and have difficulties implementing Good
Clinical Practices.
The phase III clinical trial evaluating the effectiveness of
Cellulose Sulfate (CS) for HIV and STI prevention was conducted
in five study sites over two continents [1]. Study sites differed
considerably in terms of clinical trial experience, laboratory testing
experience and even availability of laboratory infrastructures.
Only one study site in Kampala, Uganda, had all testing done
within the same facility. The other four study sites used two or
three different laboratories and the transportation of specimens
between each of them was an additional challenge. Laboratory
infrastructures varied significantly between the study sites, and in
some sites renovations had to be conducted before the study could
be set up.
Although English was the study language, Standard Operating
Procedures (SOPs) and other laboratory documents had to be
translated; communication with staff was done in French for the
Benin laboratory staff. In Mudhol, India, laboratory staff had
difficulties in reading and understanding English. Therefore
additional trainings in Kannada (the local language) had to be
organized by the local senior staff.
In this publication we present the outcome of activities
undertaken to guarantee the quality of the laboratory data in
the Phase III clinical trial of CS.
Materials and Methods
The study was a randomised, double-blind and placebo-
controlled trial of cellulose sulfate formulated as a vaginal gel
and was conducted in three African and two Indian sites. The
study was sponsored by CONRAD who selected the HIV and
Sexually Transmitted Infections Reference Laboratory from the
Institute of Tropical Medicine, Antwerp, Belgium, as the
international central reference laboratory (ICRL) for the study.
The study was approved by the Institutional Review Board of the
Eastern Virginia Medical School and of the Institute of Tropical
Medicine; and by local ethics committees at sites where women
were recruited. All approvals were granted prior study initiation.
Participants signed a written informed consent before screening
and enrolment. The trial was conducted under the Food and Drug
Administration’s Investigational New Drug application number
69,107.
Women were recruited on five different sites: a community
clinic and a sexually transmitted infections clinic in Cotonou,
Benin; the Y.R. Gaitonde Center for AIDS Research and
Education (Y.R.G. CARE) in Chennai, India; the Medical
Research Council in Durban, South Africa; Mulago Hospital
(Makerere University) in Kampala, Uganda; and in clinics in
Mudhol and Jhamkandi in Karnataka, India (a collaboration with
the Karnataka Health Promotion Trust, Bangalore).
Laboratory testing was conducted in one laboratory in
Kampala, in two laboratories in Durban and Chennai and in
three laboratories in Cotonou and Mudhol.
For sites using multiple laboratories, one of them was identified
as the local central laboratory where more sophisticated tests such
as amplification assays were performed. All study sites had at least
one small on-site laboratory where HIV rapid tests were
performed.
Role of ICRL
The ICRL gave advice on the selection of local laboratories, on
laboratory algorithms, and on the choice of tests to be used for the
study. It provided local laboratories with standardised testing
methods for the investigation of end-point results and supported
them in the redaction of SOPs. The ICRL was responsible for the
laboratory trainings, including state of the art hands-on training at
study initiation in each site, provision of control panels and
repeated testing of a subset of specimens for quality assessment
purposes. External clinical monitors also evaluated some labora-
tory aspects at each of their monthly visits. The ICRL performed
an annual supervision visit for each laboratory and participated in
the close-out visits. The first visit took place within 6 months of
study initiation.
Selection of the NG/CT amplification assay
Reliability of test results starts with the suitability of the selected
test method or technique. The investigators and ICRL decided to
use a molecular amplification assay for the determination of
genital gonococcal and chlamydial infections. All local laboratories
providing N. gonorrhoeae (NG) and C. trachomatis (CT) results had to
use the same technique and testing method. In order to assess the
interference of the CS microbicide gel on the different amplifica-
tion assays, an in vitro and in vivo study was conducted at the ICRL.
This assessment showed that the Amplicor CT/NG PCR (Roche,
Molecular Systems, Branchburg, NJ) was inhibited by the CS gel.
The SDA BD ProbeTec ET CT/NG (Becton Dickinson, Sparks,
MD) assay was not affected by the CS gel or placebo, and was
therefore selected for the clinical trial [2].
Training of the laboratories at the study sites
At each study site, the international clinical study team provided
training six weeks before study initiation on the clinical study
protocol. A staff member from the ICRL joined the international
clinical study team and conducted a separate training for all
laboratory staff. The laboratory training focused on SOPs of the
pre-analytical, the analytical and the post-analytical phase of the
study. It included: group reading and discussion of the SOPs;
problem solving exercises through case presentations; exercises
with worksheets and other study forms.
Special attention was given to the additional instructions
provided to guarantee the transparency, accuracy and reliability
of the laboratory results. At the end of the training a wrap-up
session with both clinic and laboratory teams was held to fine tune
the final decisions regarding the pre-and post-analytical proce-
dures.
Hands-on training for the selected molecular amplification assay
was organized at the ICRL premises. Shortly after or at study
initiation a follow-up training in finger-prick collection, HIV rapid
testing and molecular amplification assay was conducted at the
study site itself. Due to concerns related to safety and occupational
exposure to HIV, it was decided that the finger-prick collection
had to be performed with a Glucolet 2 automatic lancing device
(Bayer HealthCare LLC, Mishawaka,USA). None of the study
sites had any experience with this device. Although all study sites
had experience with the HIV rapid testing, the ICRL re-trained
them for reasons of standardization.
The staff member from the ICRL also provided guidance to the
external clinical monitors regarding monitoring of specific
laboratory-related issues.
Quality control activities
HIV rapid tests lot validation. All tests and reagents were
bought locally by the study sites. Verification of the new batches of
HIV rapid tests and reagents was ensured by testing a batch
validation panel prepared by the ICRL. The ICRL had to
approve the results obtained with validation panels before any new
Quality of Laboratory Data
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manufactured in the same way as the quality control panels.
Manufacturing of the panels is discussed hereafter.
Quality control panels. Every two months the study site
laboratories were asked to test a quality control (QC) panel
assembled by the ICRL, and which was identical for the different
study sites. Panels were provided for HIV rapid testing and for CT
and NG molecular amplification assay, respectively. Per test
parameter, panels consisted of the same specimens ordered
differently. For example: specimen labelled with number 1 in
panel A for HIV testing, was labelled with number 2 in panel B
and so on. A back-up from each study site panel was kept and
tested at the ICRL. The study sites tested the first panel just before
or at study initiation.
The panels for HIV quality control and HIV batch validation
consisted of 3 (2 negative and 1 HIV-positive) and 5 (3 negative
and 2 HIV- positive) specimens, respectively. The HIV negative
specimen was commercially purchased from PAA laboratories,
Pashing, Austria. It consisted of human serum type AB from
donors without AB antibodies. The positive specimens were
selected from the ICRL’s plasma collection. The collection consists
of leftover specimens previously tested for HIV diagnosis, made
anonymous and archived for future use in evaluation studies or for
inclusion in quality control panels. Specimens included in the
panels were tested at the IRCL using the HIV testing algorithm
presented in Figure 1. In addition the specimens were also tested
with the rapid tests used in the clinical trial: Determine
TM HIV1/
2, Uni-Gold
TM HIV, and SD Bioline HIV K 3.0. All HIV
positive specimens were inactivated at 56uC for 30 minutes.
Immediate action would be taken in case any of the study sites
laboratories obtained HIV testing results different from those
obtained at the ICRL.
The panels for CT and NG amplification testing were prepared
by diluting a known concentration of elementary bodies (EBs) of
CT and a known concentration of colony forming units (CFUs) of
NG in diluted Phosphate Buffered Saline (pH 7.4) (1 part of PBS
and 9 parts of saline).
The EBs of CT were obtained after culture of a Chlamydia
trachomatis L2 strain onto a monolayer of McCoy cells with
Complete Medium with Antibiotics (CMA). After 7 days of
incubation at 35uC with 5% CO2, the culture was transferred in
50 mL conical tubes and centrifuged for 3 min at 1000 rpm. The
EBs remain in suspension and the supernatant was filtered through
a 0.8 mm filter. The EBs migrate through the filter, and the
concentration of the EBs was determined by counting the EBs in
tenfold dilutions of the filtered CMA suspension in diluted PBS.
Counting was performed using an immunofluorescence colouring
test, Micro Trak C. trachomatis Culture Confirmation Reagent
(Trinity Biotech Plc, Wicklow, Ireland). Finally, 2 dilutions in PBS
(1:9, PBS:saline) containing each 3.10
6 EBs/ml and 3.10
3 EBs/ml
were included in the QC panels.
The CFUs of NG were obtained after culture of a NG ATCC
49226 strain on blood agar. A suspension of 0.5 McFarland in
diluted PBS was prepared from an overnight culture at 35uC and
5% CO2. Subsequently 10 fold dilutions were prepared from the
0.5 McFarland suspensions and from each dilution.25 ml were
spread on the surface of a blood agar with IsoVitalex (Becton-
Dickinson, Sparks, MD). Colonies were counted after an overnight
incubation at 35uC and 5% CO2. Dilutions of 10
7 and 10
4 were
selected for inclusion in the QC panel. One specimen from the
QC panel was prepared by mixing dilutions containing
3.10
4 EBs/ml and 10
5 CFUs/ml. The negative specimen consist-
ed of molecular biology grade water.
The QC panels for CT/GC contained 6 specimens of 250 mL
each. Specimens were tested at the ICRL with the SDA BD
ProbeTec ET CT/NG (Becton Dickinson, Sparks, MD) and the
Amplicor CT/NG PCR (Roche, Molecular Systems, Branchburg,
NJ) before the panels were assembled and shipped.
The study sites laboratories were allowed to miss detection of
the low concentrated specimens. However the results of the strong
Figure 1. HIV testing algorithm used for quality control and confirmation. EIA 1: EnzygnostH Anti-HIV 1/2 Plus, EIA 2: VironostikaH HIV Uni-
Form II plus O, LIA: INNO-LIA
TM HIV I/II Score. Ag: INNOTESTH HIV Antigen mAb, IND: indeterminate.
doi:10.1371/journal.pone.0013592.g001
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not, the IRCL would contact the study site and investigate the
possible cause of discordant results.
Re-testing of specimens at ICRL. Per study protocol, the
study sites had to collect two endocervical swab specimens. One
swab was tested locally; the second was stored at 220uC for future
quality control testing at the ICRL. The local laboratories shipped
all specimens positive for NG and/or CT and every tenth
specimen which tested negative for both microorganisms. The
swabs were shipped every 6 months to the ICRL, The ICRL
allowed a maximum of 5% of results obtained at the study site to
be discordant. Percentages of discordant results exceeding this
criteria, resulted in an alert signal given to the study site
laboratory, which had to stop the testing and take corrective
actions. The results obtained at the study site had to be invalidated
in case a rate of more than 15% discordance was observed.
The study sites tested serum at screening and plasma at
enrolment according to their respective national HIV testing
algorithms. A serum aliquot of all specimens tested positive for
HIV antibodies and 10% (every tenth) of the specimens which
tested negative at screening, were shipped to the ICRL every 6
months. For follow-up visits, study sites had to use a study specific
HIV testing algorithm on finger-prick blood. A plasma specimen
was collected from participants who tested positive for HIV
antibodies on the finger-prick specimen, and this was shipped to
the ICRL. All shipped specimens were re-tested for quality control
purposes and validation of results using the ICRL HIV testing
algorithm presented in Figure 1.
Reports of the results of external quality control panels testing
and of the re-testing were communicated to local laboratories.
When necessary, advice on how to improve the performance was
provided.
Shipments and transports
Commercial couriers were contracted for the overseas shipment
of study specimens and for the shipment of the QC panels from
the ICRL to the study sites.
In Benin it was not possible to contract a courier and shipment
by cargo was organised by the ICRL. The specimens were shipped
on dry ice and according to the International Air Transport
Association (IATA) regulations. Transport of the specimens within
a study site or country was under the responsibility of the study
site. For specimens that had to be kept cool or frozen, cool boxes
with ice packs or dry ice were used, respectively.
All shipments and transports were accompanied with lists
summarising the specimens included. The chain of custody was
applied as described in the study specific SOPs.
Monitoring and supervision visits
To assess day to day quality of HIV testing at study sites, the
external clinical monitors registered on a monthly basis the
number of positive test results obtained with each of the HIV rapid
tests. The study specific HIV testing algorithm consisted of serial
testing using a maximum of three rapid tests. The first rapid test
used was the Determine
TM HIV1/2 test, if this test gave a reactive
result the SD Bioline HIV K 3.0 rapid test was performed, if this
was not reactive, the Uni-Gold
TM HIV test was used. A final HIV
result was positive based on two reactive HIV rapid tests.
Discordance of test results between the first and second test and
between second and third test had to be below 5% [3].
A member of the ICRL visited the laboratories once a year, or
following special request by the study principal investigator.
During this supervision visit the raw data were examined,
equipment maintenance was checked, competence of the labora-
tory staff was assessed, the stock of reagents and consumables was
looked at and if necessary a hands-on training was provided.
Advice and corrective actions were formulated in a visit report.
Figure 2 presents the timeline of the different quality assurance/
quality control activities which are also summarized in Table 1.
Results
The laboratory supervisor or manager from each study site was
invited for a hands-on training in the SDA BD ProbeTec assay at
the ICRL. At the end of the two-week training period, trainees
received a panel of specimens to analyze. They were declared
competent if they obtained 100% correct results for the analyzed
panel and performed the testing according to the study SOP.
In order to communicate immediately HIV test results to
enrolled study participants, it was decided to perform the HIV
testing at the study clinic, using finger-prick blood and HIV rapid
tests. If the finger-prick blood was HIV-antibody positive, a second
specimen was collected and re-tested with the same HIV testing
algorithm. The participant was informed about her serostatus only
after confirmatory testing of the second specimen. Collection and
testing of this second distinct specimen was requested to control for
clerical errors or specimen mix-up. During follow-up, a total of
46/5734 specimens were initially HIV antibody positive according
to the rapid testing algorithm; however 4/46 of the second
collected specimens tested negative. The ICRL was at each
occasion informed and consulted. Additional testing and investi-
gation by the study sites, the international investigators and ICRL
could confirm that the results of the first collected specimens were
false positive reactions, and that no mixing up of specimens or
clerical error had occurred. Two false positive HIV results on the
first specimen were obtained in the same study site shortly after
Figure 2. Timeline of quality assurance activities. T: lab training, I: study initiation, M: monthly monitoring visits, Q: testing of quality control
panels, S: supervision visit, R: shipment of specimens to ICRL for re-testing.
doi:10.1371/journal.pone.0013592.g002
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guide the local laboratory staff in charge of testing, a member of
the ICRL went to the study site to examine the cause of the false
positive results. The ICRL also observed that the discordance
between the reactive HIV results obtained with the Determine test
and SD Bioline exceeded 5% in this site. One of the findings was
that the Determine test strips, once in use, were not kept according
to the manufacturer’s recommendation, i.e., in a sealed pouch
with desiccant. The strips were kept in the refrigerator. The
humidity of the refrigerator, but also of the room atmosphere,
could have deteriorated the testing device especially if left on the
bench during the day and put back in the refrigerator without
adding a desiccant. Another finding was that the results were read
as reactive by the laboratory technicians, even when only a very
faint line was visible. The laboratory staff was re-trained on the
appropriate storage of the strips and on the HIV rapid testing
procedure with special emphasis on reading and interpretation.
Information and additional instructions were also provided to the
other study sites in a preventive manner.
All new batches of HIV rapid tests and of SDA reagent passed
the lot control.
Excellent results were obtained for the quality control panels for
HIV testing, as no false results were reported by the study sites.
Among the five study sites a total of 168 control specimens,
distributed in 28 panels, were tested for CT and NG. False
negative results for CT and/or NG were obtained in each site.
Four and nine false negative results were reported for CT and NG,
respectively. The false negative results were obtained for specimens
with a lower concentration of organisms. Of the four specimens
which were reported negative for CT, 3 contained 3.10
3 EB/ml
and one 10
4 EB/ml. Of the nine specimens which were reported
negative for NG, 6 contained 10
4 CFU/ml and 3 contained
10
5 CFU/ml. None of the false negative results was caused by
inhibition. All laboratories were advised to take more care while
pipetting.
To assess the quality of the HIV serology testing, a total of 1238
out of 2916 specimens collected at screening were re-tested at the
ICRL. Through the re-testing of these specimens for HIV, the
ICRL detected in one particular site a problem of mislabelling of
specimen aliquots before storage, and of clerical errors on the
shipment list. The ICRL investigated with the concerned study site
the possible causes of these errors. Fortunately, as the mislabelling
and clerical errors occurred after the HIV rapid testing and
delivery of result to the participants, no wrong results had been
communicated to study participants. For all other study sites the
results were concordant.
The ICRL confirmed all HIV seroconversions detected during
the study using the testing algorithm presented under Figure 1.
The re-testing of endocervical specimens for CT and NG at the
ICRL showed that some sites faced a problem of DNA
contamination. To avoid further contamination and/or new
contamination problems, all study laboratories were instructed to
perform an environmental DNA check every two months. CT
and/or NG DNA contamination was detected in all study sites
laboratories performing the SDA test. The contaminated areas
included the amplification area, air conditioning, keyboard and
screen of the ProbeTec instrument, door handles, work bench, and
fridge. During the period of DNA contamination the testing was
put on hold, and resumed after thorough cleaning with bleach and
only after approval by the ICRL. Aside from the regular
environment checks, the laboratories were asked to do an extra
cleaning when more than 5% false positive results were detected
for either CT or NG following re-testing at the ICRL. This
criterion was exceeded twice by the same site, once for the CT
detection and once for the NG detection, another study site
exceeded once the criteria for the CT detection. Positive results
were considered to be false positive if the on-site positive
amplification results could not be confirmed by the ICRL. False
negative results for CT and NG was observed once in 1 study site
and false negative results for NG was observed twice in another
site, and represented less than 1% of the re-tested specimens. The
women, who were not treated due to a false negative result, were
treated at the next occasion following notification of the false
negative result. Table 2 presents the numbers and percentages of
CT and NG false results obtained in the study sites.
Discussion
The local laboratories in the CS multi-country study performed
well. All HIV seroconversions detected at the study sites were
Table 1. Overview of quality assurance/quality control activities.
Type of activity In charge Details Schedule
Supervision and training ICRL Hands on training in MAA (CT/NG SDA) at ICRL Before study initiation
Site training in study protocol (focus on pre-analytical, analytical and
post-analytical procedures)
6 weeks before study initiation
Hands on onsite training in sample collection and processing 2 weeks after study initiation
Hands on onsite training in MAA (CT/NG SDA) 2 weeks after study initiation
Supervision visit Annually and if request of site PI
Monitoring External study
monitors
Review of diagnostic tests results and lab specific aspects
(under ICRL guidance)
Monthly
Quality control for
diagnostic tests
ICRL Onsite testing of HIV and MAA QC panels At initiation and every 2 months
Re-testing for all positive and 10% negative specimens by HIV testing (serum) Every 6 months
Re-testing for all positive and 10% negative specimens by MAA testing
(endo-cervical swabs)
Every 6 months
Re-testing reports communicated to local sites 2–3 months after dispatch of
specimens to ICRL
MAA: Molecular amplification assay.
doi:10.1371/journal.pone.0013592.t001
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correct for all sites, no discordant results were obtained in the re-
testing of a sub-sample of specimens collected at screening for
HIV, except for one site, and whenever CT and/or GC DNA
contamination was detected, testing only resumed after confirmed
decontamination.
Recently a quality management system for laboratories
collaborating in clinical trials was proposed by the British
Association of Research Quality Assurance, and translated into
Good Clinical Laboratory Practices guidelines [4]. The National
Institute of Allergy and Infectious Diseases also published their
guidelines on GCLP and currently further works aiming at the
harmonization of different GCLP guidelines are ongoing [5,6].
Overall, the GCLP guidelines provide a framework on how to
deliver high quality, scientifically valid clinical trial laboratory
data. However as illustrated by Wertheim et al, challenges exist for
the implementation of these guidelines in resource constrained
settings [7]. They must be implemented in such a way that they
are in line with the realities of the setting and respond to the local
needs. Local laboratories may wish to acquire new techniques
rather than ship the specimens overseas for testing. In complement
to the procurement of new equipment and reagents, laboratory
staff needs to be trained in the maintenance of equipment,
procedure of the new technique and in assay validation. It has to
be noted that in contrast to the resource rich settings, resource
constrained settings lack logistic and technical support from
manufacturers and providers. Very often support provided by the
manufacturer remains restricted to the installation of the
equipment and demonstration of the technique. Resource rich
settings have more readily access to maintenance contracts, easy
communication, and are provided with continuous training under
the form of symposia organized by manufacturers. Therefore close
supervision is recommended at the installation of a new technique
in resource constrained settings, and once the staff is accustomed
to the technique, guidance can then be slowly phased out [8,9].
The CS trial has distinguished itself by the special emphasis put
on laboratory activities via a tailor made approach to capacity
building, monitoring and supervision of technical staff both at
initiation and throughout the study. This aspect is indeed not
routinely included or required in the set-up of clinical trials taking
place in resource rich settings, where sponsors will select
laboratories with pre-existing and well documented credentials
based on international norms. A significant aspect of capacity
building activities consisted in the provision of hands-on training
in laboratory analysis and implementation of a proficiency testing
program externally monitored by the ICRL, again not a frequent
practice in clinical trials. The role of clinical research associates
(CRAs) or study monitors is principally to train the study sites with
regards to the study protocol, rather than to ensure the oversight of
laboratory methods or to consider the implementation and
management of quality systems in the laboratory. Accordingly,
whereas source laboratory documents verification is routinely
performed by monitors and CRAs, assessment of laboratory
performance with regards to SOP compliance, or of effective
management and implementation of quality systems, is often
beyond the scope of the standard monitoring process. These
aspects rather pertain to the laboratory audit, which provide a
‘‘snap shot’’ appraisal of performance, but which purpose is not to
train on a continuous basis.
Another unique feature of the CS trial set up was the use of
custom made quality control panels for external technical
performance assessment. Although in-house quality control panels
can only be used after thorough validation of the manufacturing
process, advantages are many. Firstly, commercial quality control
panels are not always available for all parameters to be analysed.
Further, panel concentrations can be chosen in function of study-
specific end point determinations and according to the sensitivity
and specificity of laboratory methods used. Subscription to an
external and independent proficiency testing scheme could be an
option, but this would exclude the individual laboratory coaching
process specific of the CS trial. Indeed proficiency testing
providers typically give feedback on expected results to partici-
pating laboratories in the form of a detailed report, but they do not
provide individual assistance for performance improvement if
needed. It should also be noted that as participation to proficiency
testing schemes is confidential, sharing of performance related
information with study sponsors or third party is at the discretion
of the laboratory.
What would have happened if a quality assurance program had
not been included in the study specific laboratory activities? We
Table 2. Chlamydia trachomatis and Neisseria gonorrhoeae amplification re-testing results.
Site
Number of
specimens
CT + ive
results %
GC+ ive
results %
CT false +ive
results % (N)
GC false +ive
results % (N)
CT false –ive
results % (N)
GC false –ive
results % (N)
Total false
results % (N)
A 120 25.0 (30) 32.5 (39) 5.8 (7) 1.7 (2) 0 0.8 (1) 8.3 (8)
125 38.4 (48) 27.2 (34) 0.8 (1) 0.8 (1) 0 0.8 (1) 2.4 (3)
145 29.0 (42) 25.5 (37) 4.8 (7) 2.8 (4) 0 0 7.6 (11)
39 17.9 (7) 35.9 (14) 0 2.6 (1) 0 0 2.6 (1)
B 108 22.2 (24) 46.3 (50) 0.9 (1) 5.6 (6) 0 0 6.5 (7)
100 14.0 (14) 30.0 (30) 6.0 (6) 3.0 (3) 0 0 9.0 (9)
48 8.3 (4) 27.1 (13) 0 2.0 (1) 0 0 2.0 (1)
C 146 34.9 (51) 27.4 (40) 4.1 (6) 4.1 (6) 0.7 (1) 0.7 (1) 9.6 (14)
72 25.0 (18) 16.7 (12) 4.2 (3) 2.8 (2) 0 0 7.0 (5)
208 23.1 (48) 14.9 (31) 1.9 (4) 0.5 (1) 0 0 2.4 (5)
32 18.8 (6) 12.5 (4) 0 3.1 (1) 0 0 3.1 (1)
D 137 9.5 (13) 0 0 0 0 0 0
E 10 10.0 (1) 10.0 (1) 0 0 0 0 0
CT: Chlamydia trachomatis, NG: Neisseria gonorrhoeae, +ive: positive; -ive: negative, N: number.
doi:10.1371/journal.pone.0013592.t002
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site, aliquot mislabelling and clerical errors could possibly have
affected the study data. The use of an amplification assay for the
detection of CT and NG facilitated the study in terms of specimen
collection and transport, but the laboratory sites faced problems
with DNA contamination. If the contamination had not been
detected, false positive results could have been obtained leading to
over-treatment of study participants. Apart from the four HIV
false positive results on the first collected specimen and the more
than normal discordance rate between results of first and second
or third rapid HIV tests seen in one study site at the beginning of
the study, and which was readily corrected, we did not detect
problems with the HIV testing.
In summary, we were able to guarantee and to assure that
laboratory data for the endpoint determinations as stipulated by
the study protocol were reliable and of high quality. The efforts
put in capacity building of the study laboratories were very fruitful,
as none of the testing had to be repeated in the ICRL to be
included in the data base. The on site laboratories gained
experience in the performance of testing and in the documentation
required for phase III clinical trials. They acquired a new
technique, i.e., SDA, which can be used in future clinical trials or
for diagnosis if funding is available.
We also remarked that although the testing of panels for quality
control purposes could give us some indications concerning the
quality of the testing, it was through re-testing a sub-sample of the
specimens and monitoring of the in country laboratory activities that
potential major problems could be detected. Indeed we believe that
participation in external quality control or proficiency testing (PT)
schemes is not enough to measure the performance of a laboratory.
The laboratory results of EQC or PT schemes reflects the potential
analytical performance of a laboratory on the technique used, it does
not reflect the pre-analytical and/or post-analytical performances.
While designing the quality assurance program we were vigilant
to avoid overloading the local laboratory, to make it as easy as
possible, feasible and most importantly acceptable by the local
laboratory staff. We were very aware that clerical errors may be
frequent in laboratories and we therefore tried to restrict the
numbers of forms and sheets to fill in. We also wanted to be
flexible so that existing activities regarding quality control and
assurance in the local laboratory could be maintained. However
the set-up of our quality assurance program showed some
shortcomings. In our design of capacity building and quality
assurance activities we focused on the laboratory tests needed for
the endpoint determinations. We did not pay much attention to
the tests performed in the context of additional diagnosis and
treatment for other sexually transmitted or reproductive tract
infections provided as a service to the study participants. Indeed,
we observed for example that problems occurred with the
diagnosis of bacterial vaginosis. Ad hoc on-site trainings were
provided during supervision visits. Previously reported results were
questioned and corrected if necessary, but for one site we were not
able to correct the previous reported results because the biological
material and hard copy raw data had been destroyed. Strikingly,
this happened in an accredited laboratory, which sub-contracted
the laboratory testing, and provided services to many clinical trials.
This stresses the fact that working with accredited laboratories is
not a guarantee of absolute quality and that those laboratories also
need continuous guidance.
It is clear that site capacity building, in particular upgrading
laboratory facilities, and setting up a quality assurance program in
a clinical trial increases the overall study budget. These activities
ended up representing approximating 10% of the total budget for
this multi-center clinical trial but were expected to range from 5–
10% if the trial had not been terminated early. However since
most trial endpoints, including the primary endpoint in an HIV
prevention trial, are laboratory based, this extra investment is
worth the cost. The extra budget should include training of local
laboratory staff in a central laboratory and on-site, the costs of the
supervision visits, the extra time the laboratory staff spends in
applying the quality assurance or quality systems, the additional
testing ( for validation, quality control, batch validation,
environmental checks, training) requested at the local laboratory
as well as at the ICRL, the preparation and shipment of quality
control and batch panels, the shipment of specimens for re-testing
from the study site to the central laboratory, equipment
maintenance and calibration contracts.
In conclusion we want to urge sponsors to include in their clinical
trials a strong capacity building and upgrading component for the
laboratoriesthat supportthetrials.The fullapplicationofthe GCLP
guidelines in clinical trials needs appropriate resources, and we
stronglybelievethat sponsors and donorsshould consideritessential
in order to ensure the protection of participants and the reliability of
finaldata.Todatethe applicationoftheGCLPguidelines inclinical
trials has been optional, but we think that it will become a
mandatory and a necessary requirement in the near future. The
transparency, traceability and validity of the laboratory data
outweigh the extra laboratory activities and costs in clinical trials.
At the end the overall population served by the laboratory will
benefit from the upgrade of the services [10], even outside the
framework of clinical trials.
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